ReviewJournal of Alzheimer's disease : JAD2011
Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments.
Review in Journal of Alzheimer's disease : JAD, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 196 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
196 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- KL∗VS heterozygosity reduces brain amyloid in asymptomatic at-risk APOE∗4 carriers.Neurobiology of aging · 2021Pooled it
- Dementia registries around the globe and their applications: A systematic review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2017Pooled it
- Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis.Neurology · 2014Pooled it
- The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial.The journal of prevention of Alzheimer's disease · 2018Trial
- Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition.Journal of Alzheimer's disease : JAD · 2016Trial
- Social Markers of Mild Cognitive Impairment: Proportion of Word Counts in Free Conversational Speech.Current Alzheimer research · 2015Trial
- Evaluating the Accuracy of Web-Based and In-Clinic Subjective Cognitive Decline Assessments in Detecting Cognitive Impairment: Multicohort Study.Journal of medical Internet research · 2025Article
- Implications for the role of natural products in Parkinson disease therapy.Archives of medical science : AMS · 2025Article
- The ADNI Administrative Core: Ensuring ADNI's success and informing future AD clinical trials.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- The ADNI4 Digital Study: A novel approach to recruitment, screening, and assessment of participants for AD clinical research.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Article
- Effect of apolipoprotein genotype and educational attainment on cognitive function in autosomal dominant Alzheimer's disease.Nature communications · 2023Article
- Mild Behavioral Impairment in Psychogeriatric Patients: Clinical Features and Psychopathology Severity.Journal of clinical medicine · 2023Article
- Plasma p-tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Could Temperamental Features Modulate Participation in Clinical Trials?Journal of clinical medicine · 2023Article
- Autosomal dominant and sporadic late onset Alzheimer's disease share a common in vivo pathophysiology.Brain : a journal of neurology · 2022Article
- The Immune System as a Therapeutic Target for Alzheimer's Disease.Life (Basel, Switzerland) · 2022Review
- 11C-PiB PET can underestimate brain amyloid-β burden when cotton wool plaques are numerous.Brain : a journal of neurology · 2022Article
- Alzheimer's disease - the journey of a healthy brain into organ failure.Molecular neurodegeneration · 2022Review
136 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
There is an urgent need to find effective presymptomatic Alzheimer's disease (AD) treatments that reduce the risk of AD symptoms or prevent them completely. It currently takes too many healthy people, too much money and too many years to evaluate the range of promising presymptomatic treatments using clinical endpoints. We have used brain imaging and other measurements to track some of the earliest changes associated with the predisposition to AD. We have proposed the Alzheimer's Prevention Initiative (API) to evaluate investigational amyloid-modifying treatments in healthy people who, based on their age and genetic background, are at the highest imminent risk of developing symptomatic AD using brain imaging, cerebrospinal fluid (CSF), and cognitive endpoints. In one trial, we propose to study AD-causing presenilin 1 [PS1] mutation carriers from the world's largest early-onset AD kindred in Antioquia, Colombia, close to their estimated average age at clinical onset. In another trial, we propose to study apolipoprotein E (APOE) ε4 homozygotes (and possibly heterozygotes) close to their estimated average age at clinical onset. The API has several goals: 1) to evaluate investigational AD-modifying treatments sooner than otherwise possible; 2) to determine the extent to which the treatment's brain imaging and other biomarker effects predict a clinical benefit-information needed to help qualify biomarker endpoints for use in pivotal prevention trials; 3) to provide a better test of the amyloid hypothesis than clinical trials in symptomatic patients, when these treatments may be too little too late to exert their most profound effect; 4) to establish AD prevention registries needed to support these and other presymptomatic AD trials; and 5) to give those individuals at highest imminent risk of AD symptoms access to the most promising investigational treatments in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.